Strides Pharma Science Limited has successfully completed the acquisition of the remaining 50% equity stake in Neviton Softech Private Limited through its wholly owned subsidiary Arco Lab Private Limited. The transaction was finalized on February 16, 2026, transforming Neviton into a wholly owned subsidiary of Arco Lab.

Transaction Details

The acquisition involved the purchase of 5,560 equity shares representing the remaining 50% stake in Neviton from Universal Alloy Corporation Design S.R.L, a Romanian company. The transaction was executed through cash consideration.

Acquisition Timeline and Background

This acquisition represents the final phase of Arco Lab's strategic investment in Neviton. The subsidiary had previously acquired a 25% equity stake in August 2022, followed by an additional 25% stake in January 2024. With the current transaction, Arco Lab now holds 100% ownership of Neviton.

About Neviton Softech

Neviton Softech Private Limited, incorporated on February 25, 2010, operates in the IT services and engineering solutions sector. The company specializes in developing machine interfaces through IoT devices and integrating live data feeds into real-time applications. Neviton maintains operational presence in both India and USA.

Financial Performance

Neviton's financial metrics for FY25 demonstrate solid operational performance:

Three-Year Revenue Trend

Strategic Rationale

Arco Lab Private Limited was established to provide business services in driving business and IT transformation, cost efficiencies, and operational excellence, serving as a Global Life Science Capability Centre. The subsidiary also offers IT infrastructure services, enterprise application services, manufacturing IT services, new technologies, and cybersecurity services.

The acquisition enables synergies between Neviton and Arco Lab, allowing the combined entity to offer enhanced knowledge-based and IT services. This integration is expected to deliver higher scale, scope, and significant cash savings while enabling better internal group-wise digitization processes.

Regulatory Compliance

The transaction was disclosed under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. No governmental or regulatory approvals were required for the acquisition. The company confirmed that none of the promoters or promoter group of Strides Pharma Science Limited have any interest in the transaction.

Strides Pharma Science Limited announced that its subsidiary Strides Pharma Inc. (SPI) has received the USFDA Inspection Closure Report (Establishment Inspection Report – EIR) for its formulations facility located at Chestnut Ridge, New York, USA. The development marks a significant regulatory milestone for the company's U.S. operations.

Inspection Details and Timeline

The facility underwent inspection by the United States Food and Drug Administration (USFDA) from December 17, 2025 to December 23, 2025. The comprehensive inspection covered current Good Manufacturing Practices (cGMP) and included a pre-approval inspection for Drug-Device Combination capabilities, specifically covering the company's recent filing in the nasal sprays domain.

Regulatory Outcome

Based on SPI's response to the Form 483 that was issued at the conclusion of the inspection, the USFDA has classified the inspection outcome as VAI (Voluntary Action Indicated). The EIR confirms that the inspection has been officially closed, providing regulatory clearance for the facility's operations.

Facility Capabilities and Market Focus

The Chestnut Ridge facility serves the U.S. market exclusively and maintains diverse manufacturing capabilities. The facility produces liquids, gels, hormones, modified release products and controlled substances, supporting several current and future products for the U.S. market. The successful closure of this inspection, including device combinations, further strengthens the company's U.S. business and near-term growth prospects.

Strategic Significance

The inspection closure represents a crucial development for Strides' U.S. operations, particularly in expanding capabilities for drug-device combinations in the nasal sprays segment. This regulatory approval enables the company to advance its product pipeline and strengthen its position in specialized pharmaceutical manufacturing.

About Strides

Strides is a global pharmaceutical company headquartered in Bengaluru, India, listed on BSE Limited and National Stock Exchange of India Limited. The company operates manufacturing sites across India, Italy, Kenya, and the United States, focusing on "difficult to manufacture" products sold in over 100 countries. The company maintains an "in Africa for Africa" strategy and serves institutional business in donor-funded markets.

Strides remains committed to maintaining the highest standards of regulatory compliance and continues to focus on manufacturing high-quality pharmaceutical products for global markets.